Trial
NCT02768532
Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Collaborators
Theradiag; Takeda
Condition
Crohn Disease
Intervention
Vedolizumab
Why stopped
low inclusion rates
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-15